John K. Lee PhD

John K. Lee, MD, PhD

Associate Professor, Department of Medicine, Division of Hematology/Oncology





Hematology and Oncology, University of California, Los Angeles, 2014
Cancer Biology, University of California, Los Angeles, 2018


PhD, University of California, Los Angeles, 2016
MD, Geisel School of Medicine at Dartmouth, Hanover, NH, 2006
AB, Harvard College, Cambidge, MA, 2001


Internal Medicine, Boston University School of Medicine, Boston, MA, 2009

Contact Information

Scientific Interests

Dr. Lee's research interests are to identify molecular drivers and biological properties of prostate and bladder cancer that may be exploited for the development of new and effective targeted treatments. Recent studies are focused on untangling diverse genotype-phenotype relationships in cancer using combinatorial genetics approaches and developing cell-based immunotherapies for clinical translation.

Highlighted Publications

DeLucia DC, Cardillo T, Ang L, Labrecque MP, Zhang A, Hopkins JE, Gil da Costa RM, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN-38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res. 2021 Feb 1;27(3):759-774. doi: 10.1158/1078-0432.CCR-20-3396. PMID: 33199493.

Mao Z, Nesterenko PA, McLaughlin J, Deng W, Sojo GB, Cheng D, Noguchi M, Chour W, DeLucia DC, Finton KA, Qin Y, Obusan MB, Tran W, Wang L, Bangayan NJ, Ta L, Chen CC, Seet CS, Crooks GM, Phillips JW, Heath JR, Strong RK, Lee JK, Wohlschlegel JA, Witte ON. Combined physical and in silico immunopeptidomic profiling of the cancer antigen prostatic acid phosphatase reveals peptide targets enabling cognate TCR isolation. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2203410119. doi: 10.1073/pnas.2203410119. PMID: 35878026.

Bhatia V*, Kamat NV*, Pariva TE*, Wu L, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J#, Lee JK#. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. PMID: 37041154.

Li S*, Wong A*, Sun H*, Bhatia V, Javier G, Jana S, Montgomery RB, Wright JL, Lam H-M, Hsieh AC, Faltas BM, Haffner MC, Lee JK. Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations. bioRxiv. 2023 Apr 14. doi: 10.1101/2023.04.12.536652.

Xu AM, Xu AM, Chour W, DeLucia DC, Su Y, Pavlovitch-Bedzyk AJP, Ng R, Rasheed Y, Davis M, Lee JK, Heath JR. Entropic analysis of antigen-specific CDR3 domains identifies essential binding motifs shared by CDR3s with different antigen specificities. Cell Syst. 2023 Apr 19;14(4):273-284.e5. doi: 10.1016/j.cels.2023.03.001. PMID: 37001518.